At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We believe transparency is an important part of our ongoing collaboration with the health care community, helping to build a community of trust and respect with healthcare professionals, patients, industry peers, stockholders and the public.
We are committed to acting with integrity, which is the foundation on which we build our business. Our operations adhere to the highest standards and our company puts our values into action each day, according to our Code of Business Conduct.
Payments to Health Care Professionals
We are committed to meeting all global transparency requirements, including the Physician Payments Sunshine Act in the United States and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code in the European Union. As is our obligation, we record all transfers of value to certain health care professionals and organizations and report pursuant to the applicable local codes and laws. We take care to ensure that the data that we submit is as detailed, comprehensive and clear as possible. Ultimately, the data we submit today can benefit patients in the future.
In the United States, we report in accordance with the Physician Payments Sunshine Act passed in 2010. Our data regarding payments to health care professionals publicly accessible via the Centers for Medicare and Medical Services Open Payments Program.
In the European Union, we are a member of EFPIA, and endorse the EFPIA Disclosure Code, a set of guiding principles that requires pharmaceutical companies to publicly disclose transfers of value made to European health care professionals and health care organizations.
We are committed to improving the lives of people living with devastating conditions and advancing scientific understanding of the diseases we aim to treat. To that end, we support independent initiatives through advocacy organizations and independent medical education.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.